kc 764 has been researched along with thromboxane b2 in 2 studies
| Studies (kc 764) | Trials (kc 764) | Recent Studies (post-2010) (kc 764) | Studies (thromboxane b2) | Trials (thromboxane b2) | Recent Studies (post-2010) (thromboxane b2) |
|---|---|---|---|---|---|
| 9 | 1 | 0 | 7,483 | 715 | 485 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohkubo, H; Ohmuro, S; Taga, F; Tsukada, Y; Uchida, H | 1 |
| Hiramoto, M; Imaizumi, TA; Koyama, M; Satoh, K; Takamatsu, S; Yoshida, H | 1 |
1 trial(s) available for kc 764 and thromboxane b2
| Article | Year |
|---|---|
Pyrazolopyridine derivative acts as a novel cyclooxygenase inhibitor: antiplatelet effect in aged patients with ischemic stroke.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Aged; Aged, 80 and over; Brain Ischemia; Bridged Bicyclo Compounds; Cerebrovascular Disorders; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Nicotinic Acids; Platelet Aggregation Inhibitors; Thromboxane B2 | 1994 |
1 other study(ies) available for kc 764 and thromboxane b2
| Article | Year |
|---|---|
Protective effect of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on myocardial damage due to coronary occlusion and reperfusion in rabbit.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspartate Aminotransferases; Aspirin; Bridged Bicyclo Compounds; Chemotaxis, Leukocyte; Creatine Kinase; Guinea Pigs; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardial Reperfusion Injury; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Nicotinic Acids; Platelet Aggregation Inhibitors; Rabbits; Thromboxane B2 | 1992 |